Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812 click here By John Harbison|2017-02-20T06:55:21-08:00November 11, 2016|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812 Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkXingEmail About the Author: John Harbison Related Posts
